<DrugInformationSummary id="CDR0000797206"><DrugInfoMetaData><DrugInfoType>Brief</DrugInfoType><DrugInfoAudience>Patients</DrugInfoAudience><DrugInfoDescription>Trastuzumab and hyaluronidase-oysk  consists of a combination of the monoclonal antibody trastuzumab and a recombinant enzyme called hyaluronidase-oysk, which allows trastuzumab to more easily enter tissues. Trastuzumab binds to HER2, a protein found in high levels on some cancer cells and causes them to grow. This binding blocks the ability of HER2-positive cancer cells to send chemical signals that tell them to grow. It also stimulates the immune system to kill cells that have a lot of HER2. Trastuzumab and hyaluronidase-oysk is a type of targeted therapy drug.</DrugInfoDescription><DrugInfoURL xref="https://www.cancer.gov/about-cancer/treatment/drugs/trastuzumabandhyaluronidase-oysk">Trastuzumab and Hyaluronidase-oysk</DrugInfoURL><FDAApproved>Yes</FDAApproved><TerminologyLink ref="CDR0000797111">trastuzumab and hyaluronidase-oysk</TerminologyLink><GlossaryLink ref="CDR0000797117">trastuzumab and hyaluronidase</GlossaryLink><USBrandNames><USBrandName>Herceptin Hylecta</USBrandName></USBrandNames><PronunciationInfo><TermPronunciation>tras-TOO-zoo-mab â€¦ HY-al-yoo-RAH-nih-days</TermPronunciation><MediaLink ref="CDR0000798007" type="audio/mpeg" alt="" language="en" id="_3"/><MediaLink ref="CDR0000798008" type="audio/mpeg" alt="" language="es" id="_6"/></PronunciationInfo><FDAExternalRef xref="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ebf30894-41cf-480c-8bc3-56f592a13813">FDA label information for this drug is available at DailyMed.</FDAExternalRef></DrugInfoMetaData><DrugInfoTitle>Trastuzumab and Hyaluronidase-oysk</DrugInfoTitle><Section id="_FDA"><Para><ExternalRef xref="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ebf30894-41cf-480c-8bc3-56f592a13813">FDA label information for this drug is available at DailyMed.</ExternalRef></Para></Section><Section id="_1"><Title>Use in Cancer</Title>                                                              
  <Para id="_2">Trastuzumab and hyaluronidase-oysk
         is approved to treat:</Para>                          
  <ItemizedList Style="bullet" id="_3">
   <ListItem><Strong><GlossaryTermRef href="CDR0000444971" dictionary="Cancer.gov" audience="Patient">Breast cancer</GlossaryTermRef></Strong> that is <GlossaryTermRef href="CDR0000737998" dictionary="Cancer.gov" audience="Patient">HER2 positive</GlossaryTermRef> (HER2+). It is used in adults with:<ItemizedList Style="bullet" id="_4"><ListItem><GlossaryTermRef href="CDR0000788033" dictionary="Cancer.gov" audience="Patient">Hormone receptor-negative</GlossaryTermRef> or <GlossaryTermRef href="CDR0000045079" dictionary="Cancer.gov" audience="Patient">high-risk</GlossaryTermRef> cancer. It is given:<ItemizedList Style="bullet" id="_5"><ListItem>as <GlossaryTermRef href="CDR0000045650" dictionary="Cancer.gov" audience="Patient">combination chemotherapy</GlossaryTermRef> with:<ItemizedList Style="bullet" id="_6"><ListItem><GlossaryTermRef href="CDR0000560140" dictionary="Cancer.gov" audience="Patient">doxorubicin</GlossaryTermRef>, <GlossaryTermRef href="CDR0000045253" dictionary="Cancer.gov" audience="Patient">cyclophosphamide</GlossaryTermRef>, and either <GlossaryTermRef href="CDR0000045258" dictionary="Cancer.gov" audience="Patient">paclitaxel</GlossaryTermRef> or <GlossaryTermRef href="CDR0000045382" dictionary="Cancer.gov" audience="Patient">docetaxel</GlossaryTermRef>; or</ListItem><ListItem>docetaxel and <GlossaryTermRef href="CDR0000045182" dictionary="Cancer.gov" audience="Patient">carboplatin</GlossaryTermRef></ListItem></ItemizedList></ListItem><ListItem>alone after combination therapy that included <GlossaryTermRef href="CDR0000044916" dictionary="Cancer.gov" audience="Patient">anthracycline</GlossaryTermRef> chemotherapy</ListItem></ItemizedList></ListItem><ListItem><GlossaryTermRef href="CDR0000044058" dictionary="Cancer.gov" audience="Patient">Metastatic</GlossaryTermRef> cancer. It is given:<ItemizedList Style="bullet" id="_7"><ListItem>with paclitaxel for <GlossaryTermRef href="CDR0000346494" dictionary="Cancer.gov" audience="Patient">first-line treatment</GlossaryTermRef>; or</ListItem><ListItem>alone in patients who have already been treated with at least one chemotherapy <GlossaryTermRef href="CDR0000045864" dictionary="Cancer.gov" audience="Patient">regimen</GlossaryTermRef> given for metastatic cancer</ListItem></ItemizedList></ListItem></ItemizedList></ListItem>
   </ItemizedList>
  <Para id="_8">Trastuzumab and hyaluronidase-oysk
         is a form of trastuzumab that is given as a <GlossaryTermRef href="CDR0000045914" dictionary="Cancer.gov" audience="Patient">subcutaneous</GlossaryTermRef> <GlossaryTermRef href="CDR0000044678" dictionary="Cancer.gov" audience="Patient">injection</GlossaryTermRef>. This form can be given in less time than trastuzumab, which is given as an <GlossaryTermRef href="CDR0000045738" dictionary="Cancer.gov" audience="Patient">infusion</GlossaryTermRef>. For more information about trastuzumab that may apply to trastuzumab and hyaluronidase-oysk, see the Drug Information Summary for <DrugRef href="CDR0000502211" url="/about-cancer/treatment/drugs/trastuzumab">Trastuzumab</DrugRef>.</Para>
 </Section><Section id="_About"><Title>More About Trastuzumab and Hyaluronidase-oysk</Title><Para id="_Dict_1"><ExternalRef xref="https://www.cancer.gov/publications/dictionaries/cancer-drug/def/797111">Definition from the NCI Drug Dictionary</ExternalRef> - Detailed scientific definition and other names for this drug.</Para>

<Para id="_About_8.30">MedlinePlus Information on <ExternalRef xref="https://medlineplus.gov/druginfo/meds/a619041.html">Trastuzumab and Hyaluronidase-oysk</ExternalRef> - A lay language summary of important information about this drug that may include the following:</Para>
<ItemizedList Style="bullet" id="_About_9.31"><ListItem>warnings about this drug,</ListItem><ListItem>what this drug is used for and how it is used,</ListItem><ListItem>what you should tell your doctor before using this drug,</ListItem><ListItem>what you should know about this drug before using it, </ListItem><ListItem>other drugs that may interact with this drug, and</ListItem><ListItem>possible side effects.  </ListItem></ItemizedList><Para id="_About_10.32">Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for.  This patient information sheet applies only to approved uses of the drug.  However, much of the information may also apply to unapproved uses that are being studied.</Para></Section><Section id="_Research"><Title>Research Results and Related Resources</Title><Para><ExternalRef xref="https://www.cancer.gov/about-cancer/treatment/types/targeted-therapies">Targeted Therapy to Treat Cancer</ExternalRef></Para><Para><ExternalRef xref="https://www.cancer.gov/about-cancer/treatment/types/immunotherapy/monoclonal-antibodies">Monoclonal Antibodies</ExternalRef></Para></Section><Section id="_ClinicalTrial_1"><Title>Clinical Trials Accepting Patients</Title><Para id="_ClinicalTrial_2"><ExternalRef xref="https://www.cancer.gov/research/participate/clinical-trials/intervention/C158060">Find Clinical Trials for Trastuzumab And Hyaluronidase-oysk</ExternalRef> - Check for trials from NCI's list of cancer clinical trials now accepting patients.</Para></Section> 
  <DrugInfoDisclaimer>


<Para id="_Disclaimer_4"><Strong>Important: </Strong>The drug information on this page is meant to be educational. It is not a substitute for medical advice. The information may not cover all possible uses, actions, interactions, or side effects of this drug, or precautions to be taken while using it. Please see your health care professional for more information about your specific medical condition and the use of this drug.
</Para></DrugInfoDisclaimer> 
  <DateFirstPublished>2019-03-14</DateFirstPublished><DateLastModified>2024-12-20</DateLastModified></DrugInformationSummary>
